Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

First patient dosed in Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

August 9, 2023

Ph 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer Initiated

August 9, 2023

Phase 3 Study of V940 (mRNA-4157) + KEYTRUDA initiated for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma

August 2, 2023

Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS To Discontinue

August 2, 2023

First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

August 2, 2023

Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients to be discontinued

August 2, 2023

First Patient Dosed with ELU001 in Expansion Cohort of Phase 1/2 Clinical Trial

July 27, 2023

Ph 3 ENHANCE Study Of Magrolimab Plus Azacitidine In Higher-Risk MDS To Discontinue

July 27, 2023

Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients Announced

July 19, 2023

Enrollment in Ph 1/2 Study Discontinued; Development of THE-630 in Patients with GIST Terminated

July 19, 2023

Enrollment Update Provided for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

July 19, 2023

Voluntary Pause of Enrollment in the Ph 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients Announced

July 19, 2023

First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer

July 19, 2023

FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID

July 12, 2023

First patient dosed in Ph 2 MATISSE study in combination with durvalumab and chemotherapy in treatment-naïve patients with resectable early stage NSCLC

July 5, 2023

Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer initiated

July 5, 2023

Enrollment completed in Pivotal Phase 3 TiNivo-2 Study of FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) in Advanced Renal Cell Carcinoma

July 5, 2023

Pivotal Ph 3 Study of Selinexor and Ruxolitinib in JAKi-Naïve Myelofibrosis initiated

July 5, 2023

Pivotal Phase 3 Trial of BNT316/ONC-392 Program in mNSCLC initiated

July 5, 2023

First Patient dosed in Ph 1 Study of Cancer Vaccine CVGBM for Surgically Resected Glioblastoma

June 28, 2023

First Patients Dosed in Ph 2 Liver Cancer Trial of TTI-101

June 28, 2023

Clinical Hold Announced for iMMagine-1 Ph 2 Clinical Program

June 28, 2023

First Patient Dosed in Ph 2a Clinical Trial of GFH009 in AML

June 28, 2023

First Patient Dosed in Ph 1 Trial of Briquilimab in Lower-Risk MDS

June 28, 2023

First Patient Dosed in Ph 2 IMpress Trial of Imetelstat in Patients with R/R AML or Higher Risk MDS

June 21, 2023
Page1 … Page15 Page16 Page17 Page18 Page19 … Page22

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.